Literature DB >> 11369991

Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited.

E Kebebew1, P A Treseler, P H Ituarte, O H Clark.   

Abstract

The effect of chronic lymphocytic thyroiditis (CLT) on the behavior of papillary thyroid cancer (PTC) remains unclear. In recent studies the presence of CLT in patients with PTC was reported to be associated with a lower recurrence rate and an improved survival rate. Furthermore, patients with PTC and tumor infiltrating lymphocytes (TILs) have been reported to have lower recurrence rates and a lower frequency of distant metastases. Because of these and other observations, a tumor immune response in PTC has been suggested. The aim of our study was to determine: (1) the relative frequency of CLT in PTC; (2) the prognostic significance of CLT in patients with PTC; and (3) if TIL occurs independently or in association with CLT. A 10-year retrospective study of patients who underwent initial thyroidectomy for PTC from 1986 to 1996 was completed. The extent of thyroid lymphocytic infiltration was determined within the tumor, surrounding the tumor, and in the distant parenchyma by two independent observers blinded to the clinical data. Dense focal/diffuse lymphoid aggregates throughout the thyroid gland were diagnostic of CLT and when present within or surrounding the tumor were designated TILs. A total of 136 patients with PTC (typical and follicular variant of PTC histologic subtypes) were identified with a mean follow-up of 4.4 years and a 8% mortality rate at 10 years. Thirty percent of the patients with PTC had coexisting CLT, and 65% of these patients with CLT had positive anti-thyroglobulin antibodies. Patients with coexisting CLT and PTC were younger (p < 0.05), more likely to be female (p < 0.05), and more likely to have multicentric tumors (p < 0.001) compared to patients without CLT. Only 5% of patients had TILs without CLT, but 82.5% of patients with CLT had TILs identified (p < 0.0001). By univariate analysis CLT, age, gender, stage of PTC, tumor multicentricity, and tumor size were significant prognostic factors. Only age and TNM stage of PTC remained independent prognostic factors by multivariate analysis. We found a similar frequency (30%) of coexisting CLT and PTC as reported by others; but, more importantly, the presence of TILs primarily occurred in association with CLT. The presence of CLT in patients with PTC correlated with an improved prognosis. It was not an independent prognostic factor, however, and was not associated with a lower recurrence rate or a lower frequency of distant metastasis.

Entities:  

Mesh:

Year:  2001        PMID: 11369991     DOI: 10.1007/s002680020165

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  60 in total

1.  Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis.

Authors:  Jennifer L Hunt; Zubair W Baloch; Leon Barnes; Patricia A Swalsky; Cindy L Trusky; E Sesatomi; Sydney Finkelstein; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

2.  The impact of coexistent Hashimoto's thyroiditis on lymph node metastasis and prognosis in papillary thyroid microcarcinoma.

Authors:  Ning Qu; Ling Zhang; Dao-Zhe Lin; Qing-Hai Ji; Yong-Xue Zhu; Yu Wang
Journal:  Tumour Biol       Date:  2015-12-21

3.  The clinicopathologic differences of central lymph node metastasis in predicting lateral lymph node metastasis and prognosis in papillary thyroid cancer associated with or without Hashimoto's thyroiditis.

Authors:  Youzhi Zhu; Ke Zheng; Huihao Zhang; Ling Chen; Jiajie Xue; Mingji Ding; Kunlin Wu; Zongcai Wang; Lingjun Kong; Xiangjin Chen
Journal:  Tumour Biol       Date:  2015-12-28

4.  Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies.

Authors:  Cosimo Durante; Sara Tognini; Teresa Montesano; Fabio Orlandi; Massimo Torlontano; Efisio Puxeddu; Marco Attard; Giuseppe Costante; Salvatore Tumino; Domenico Meringolo; Rocco Bruno; Fabiana Trulli; Maria Toteda; Adriano Redler; Giuseppe Ronga; Sebastiano Filetti; Fabio Monzani
Journal:  Thyroid       Date:  2014-05-21       Impact factor: 6.568

5.  Chronic lymphocytic thyroiditis does not influence the risk of recurrence in patients with papillary thyroid carcinoma and excellent response to initial therapy.

Authors:  Marina S Carvalho; Pedro W Rosario; Gabriela F Mourão; Maria R Calsolari
Journal:  Endocrine       Date:  2016-11-23       Impact factor: 3.633

6.  Minimally invasive video-assisted thyroidectomy: an analysis of results and a revision of indications.

Authors:  Michele N Minuto; Piero Berti; Mario Miccoli; Clara Ugolini; Valeria Matteucci; Manuela Moretti; Fulvio Basolo; Paolo Miccoli
Journal:  Surg Endosc       Date:  2011-10-25       Impact factor: 4.584

7.  Is diffuse and peritumoral lymphocyte infiltration in papillary thyroid cancer a marker of good prognosis?

Authors:  D G P N Villagelin; R B Santos; J H Romaldini
Journal:  J Endocrinol Invest       Date:  2011-07-13       Impact factor: 4.256

8.  Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: the potential key role of Foxp3+ T lymphocytes.

Authors:  T Pilli; P Toti; R Occhini; M G Castagna; S Cantara; M Caselli; S Cardinale; L Barbagli; F Pacini
Journal:  J Endocrinol Invest       Date:  2017-12-11       Impact factor: 4.256

9.  Papillary thyroid cancer, although strongly associated with lymphocytic infiltration on histology, is only weakly predicted by serum thyroid auto-antibodies in patients with nodular thyroid diseases.

Authors:  E Fiore; T Rago; M Scutari; C Ugolini; A Proietti; G Di Coscio; M A Provenzale; P Berti; L Grasso; S Mariotti; A Pinchera; P Vitti
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256

10.  Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas.

Authors:  Ove Bruland; Øystein Fluge; Lars A Akslen; Hans G Eiken; Johan R Lillehaug; Jan E Varhaug; Per M Knappskog
Journal:  BMC Cancer       Date:  2009-12-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.